Ann Clin Neurophysiol.
2024 Oct;26(2):54-56. 10.14253/acn.24001.
Early relapse after rituximab treatment in a patient with seronegative neuromyelitis optica spectrum disorder: a case report
- Affiliations
-
- 1Department of Neurology, Kangwon National University Hospital, Chuncheon, Korea
- 2Department of Translational Medicine, Seoul National University College of Medicine, Seoul, Korea
- 3Department of Neurology, Seoul National University Seoul Metropolitan Government Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea
- KMID: 2560432
- DOI: http://doi.org/10.14253/acn.24001
Abstract
- Rituximab (RTX) is a monoclonal antibody that targets CD20 on B cells and is used to reduce the relapse risk in neuromyelitis optica spectrum disorder (NMOSD). Some patients experience relapse or exacerbation shortly after RTX treatment. We report a 54-year-old female with seronegative NMOSD who relapsed soon after RTX treatment.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Postpartum Relapse of Neuromyelitis Optica Spectrum Disorder after a Long Period of Spontaneous Remission
- Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder Triggered by Herpes Zoster: A Case Report and Literature Review
- Monoclonal Antibody Treatment for Relapse Prevention in Neuromyelitis Optica Spectrum Disorder
- Differential Diagnosis between Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder
- Late-onset Seronegative Neuromyelitis Optica Spectrum Disorder Mimicking Wernicke Encephalopathy
